Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC25A | P30304 | 4/20 | 0.65 |
| ▸ | POLA1 | P09884 | 1/20 | 0.65 |
| ▸ | USP2 | O75604 | 1/20 | 0.56 |
| ▸ | VDR | P11473 | 1/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
| ▸ | INPP5D | Q92835 | 1/20 | 0.54 |
| ▸ | ST6GAL1 | P15907 | 2/20 | 0.52 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21298903 | 1.00 | CDC25A (0.65) | CDC25APOLA1USP2VDRCYP2D6 | |
| SCHEMBL19722016 | 1.00 | CDC25A (0.65) | CDC25APOLA1USP2VDRCYP2D6 | |
| SCHEMBL19722456 | 0.91 | CDC25A (0.62) | CDC25APOLA1USP2VDRCYP2D6 | |
| SCHEMBL21298955 | 0.91 | CDC25A (0.62) | CDC25APOLA1USP2VDRCYP2D6 | |
| SCHEMBL19755107 | 0.91 | CDC25A (0.62) | CDC25APOLA1USP2VDRCYP2D6 | |
| SCHEMBL19855002 | 0.91 | CDC25A (0.62) | CDC25APOLA1USP2VDRCYP2D6 | |
| SCHEMBL21298906 | 0.90 | CDC25A (0.68) | CDC25APOLA1USP2VDRCYP2D6 | |
| SCHEMBL19755059 | 0.90 | CDC25A (0.68) | CDC25APOLA1USP2VDRCYP2D6 | |
| SCHEMBL19854979 | 0.90 | CDC25A (0.53) | CDC25APOLA1USP2VDRCYP2D6 | |
| SCHEMBL21298976 | 0.90 | CDC25A (0.70) | CDC25APOLA1USP2VDRCYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210214615-A1 | LIQUID CRYSTAL DISPLAY DEVICE AND DISPLAY UNIT | JNC CORPORATION (JP) | 2021-07-15 | — | — | US | disclosed |
| US-10392339-B2 | Polymerizable polar compound, liquid crystal composition, and liquid crystal display element | JNC CORPORATION (JP) | 2019-08-27 | — | — | US | disclosed |
| US-20170369418-A1 | POLYMERIZABLE POLAR COMPOUND, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY ELEMENT | JNC CORPORATION (JP) | 2017-12-28 | — | — | US | disclosed |
| EP-3257839-A1 | POLYMERIZABLE POLAR COMPOUND, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY ELEMENT | JNC Corporation (JP) | 2017-12-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10392339-B2 | Polymerizable polar compound, liquid crystal composition, and liquid crystal display element | SP1, HVCN1, CXCR1 | CDC25A 105/4885POLA1 1041/4885USP2 3703/4885 |
| US-20170369418-A1 | POLYMERIZABLE POLAR COMPOUND, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY ELEMENT | SP1, SPIN1, SAV1 | CDC25A 83/4885POLA1 983/4885USP2 3567/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.